Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
CytomX Therapeutics Inc Market Cap
Based on ratings from 7 stock analysts, the CytomX Therapeutics Inc stock price is expected to increase by 324.8% in 12 months. This is calculated by using the average 12-month stock price forecast for CytomX Therapeutics Inc. The lowest target is $3.5 and the highest is $8. Please note analyst price targets are not guaranteed and could be missed completely.
About 7 Wall Street analysts have assigned CTMX 6 buy ratings, 1 hold ratings, and 0 sell ratings. This means that analysts expect CytomX Therapeutics Inc to outperform the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on CTMX. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of CTMX.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Mitchell Kapoor HC Wainwright & Co. | Neutral | Reiterates | Aug 22, 2024 | |
| Mitchell Kapoor HC Wainwright & Co. | Neutral | Reiterates | Jun 27, 2024 | |
| Joseph Catanzaro Piper Sandler | Overweight | $3.5 | Upgrade | May 28, 2024 |
| Mitchell Kapoor HC Wainwright & Co. | Neutral | Reiterates | May 9, 2024 | |
| Robert Driscoll Wedbush | Outperform | $8 | Upgrade | May 9, 2024 |
| Etzer Darout BMO Capital | Market Perform | $3.59 | Maintains | May 9, 2024 |
| Roger Song Jefferies | Buy | $8 | Upgrade | May 6, 2024 |
| Etzer Darout BMO Capital | Market Perform | $3.25 | Reiterates | May 1, 2024 |
| Anupam Rama JP Morgan | Neutral | Upgrade | Apr 22, 2024 | |
| Robert Driscoll Wedbush | Neutral | $3 | Reiterates | Mar 12, 2024 |
| Etzer Darout BMO Capital | Market Perform | $3.25 | Maintains | Mar 12, 2024 |
| Robert Driscoll Wedbush | Neutral | $3 | Maintains | Nov 9, 2023 |
| Robert Driscoll Wedbush | Outperform | $3 | Upgrade | Nov 8, 2023 |
| Etzer Darout BMO Capital | Market Perform | $3.19 | Maintains | Aug 9, 2023 |
| Mara Goldstein Mizuho | Neutral | $2 | Maintains | Mar 28, 2023 |
| Etzer Darout BMO Capital | Market Perform | $3.2 | Maintains | Jan 6, 2023 |
| Etzer Darout BMO Capital | Market Perform | $2.6 | Downgrade | Nov 14, 2022 |
| Anupam Rama JP Morgan | Underweight | Downgrade | Nov 10, 2022 | |
| Mitchell Kapoor HC Wainwright & Co. | Neutral | Downgrade | Jul 11, 2022 | |
| Boris Peaker Cowen & Co. | Market Perform | Downgrade | Jul 11, 2022 |
When did it IPO
2015
Staff Count
120
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Sean A. McCarthy DPHIL
Market Cap
$93.0M
In 2023, CTMX generated $101.2M in revenue, which was a increase of 90.38% from the previous year. This can be seen as a signal that CTMX's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Thu, 08 Aug 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - - CX-904 (EGFR-CD3 PROBODY® T-cell engager) Phase 1a enrollment continues, primarily focused in PDAC, NSCLC, and HNSCC. Program update expected by the end of 2024 -
Mon, 17 Jun 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - SOUTH SAN FRANCISCO, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the promotion of Chris Ogden to Chief Financial Officer effective June 15, 2024.
Tue, 18 Jun 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - SOUTH SAN FRANCISCO, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in a fireside chat at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference on Tuesday, June 25, 2024, at 2:00 p.m. ET.
Wed, 05 Jun 2024
Sentiment - POSITIVE
Source - InvestorPlace
Summary - When the term penny stocks to buy is thrown around, ideas of high-risk-high-reward, overnight wealth generation and potential scams may come to mind. However, investing in carefully-selected penny stocks can yield a much less volatile experience.
Wed, 29 May 2024
Sentiment - NEUTRAL
Source - InvestorPlace
Summary - Not long ago, GameStop (NYSE: GME ) stock soared and then tanked on the meme-stock waves. A company that went along for the ride was CytomX Therapeutics (NASDAQ: CTMX ), as CytomX Therapeutics stock took a round trip from $1.80 to $5.80 and back.
Wed, 22 May 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - SOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will present at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024, at 8:30 a.m. ET.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
